NEW YORK, Dec. 10, 2025 /PRNewswire/ -- Apple Tree Partners ("ATP"), a
leading life sciences venture capital firm, has announced that on
December 9, 2025, certain ATP affiliates filed voluntary petitions for
Chapter 11 relief in the United States Bankruptcy Court for the District
of Delaware (the "Court") in order to implement a restructuring plan to
ensure its portfolio companies have the funding and resources required
to continue their critical missions to research and develop novel
breakthrough treatments for cancer, neurological disorders, infectious
diseases, and other serious diseases. Since its inception more than 25
years ago, ATP has delivered an industry-leading DPI of 1x on $2.5
billion. The firm's debut fund, ATP I, stands as the second-highest
returning fund globally for its vintage (1999). Its most recent fund,
ATP Life Science Ventures, has best-in-class performance over 12 years
with a net TVPI of 2.7x and a net DPI of 1.0x.
ATP and its affiliates will continue to operate during the
reorganization.
"We undertake this restructuring to serve the best interests of our
limited partners, our portfolio companies, their employees and founders,
the health care professionals and institutions who partner with us in
researching and developing new medical treatments, and ultimately, the
patients who stand to benefit from everyone's invention, dedication,
risk, and effort," said Seth Harrison, M.D., founder and Managing
Partner, ATP. "We have no doubt that the fundamentals underpinning our
investments are strong, and that our portfolio companies have shown and
continue to show great promise to deliver significant returns on
investment and meaningful new treatments and cures."
ATP has retained B. Riley as financial and restructuring advisor to the
firm, with Perry Mandarino, Senior Managing Director of B. Riley, as
Chief Restructuring Officer. Quinn Emanuel Urquhart & Sullivan, LLP and
Potter, Anderson & Corroon LLP have been appointed general bankruptcy
co-counsels.
About Apple Tree Partners
Apple Tree Partners (ATP) is a leader in life sciences venture capital.
ATP creates companies starting at various stages, from pre-IP ideas to
asset spinouts, investing in them from seed stage through IPO and
beyond. The core of ATP's strategy is providing flexible capital and
access to a world-class team of venture partners and EIRs, to build
sustainable, research-driven enterprises that deliver therapeutics to
improve human lives. For more information, visit
www.appletreepartners.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/apple-tree-partners-initiates-voluntary-us-chapter-11-cases-in-delaware-to-restructure-operations-302638211.html
SOURCE Apple Tree Partners
(END) Dow Jones Newswires
December 10, 2025 11:59 ET (16:59 GMT)
Comments